Yumanity Therapeutics
yeast, neurodegeneration, brain drugs
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companies
C-KK7G
yeast, neurodegeneration, brain drugs
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Yumanity Therapeutics yeast, neurodegeneration, brain drugs
Yumanity Therapeutics was a Boston-based developer of brain drugs focused on neurodegenerative diseases. The company used yeast as an unorthodox tool to better understand disease biology and find potential treatments. In 2022, it announced plans to sell most research assets to Janssen and merge with Kineta, ending its run as an independent biotechnology company.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Yumanity Therapeutics — Translational · Lower middle. Derived deterministically from 5 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic